Skip to main content

25.03.2020 | Original Article

Implementation of a molecular tumor board at a regional level to improve access to targeted therapy

International Journal of Clinical Oncology
Héloïse Bourien, Alexandra Lespagnol, Boris Campillo-Gimenez, Ingrid Felten-Vinot, Jean-Philippe Metges, Romain Corre, Thierry Lesimple, Cédric le Marechal, Lise Boussemart, Solène-Florence Kammerer-Jacquet, Edouard le Gall, Florent Denoual, Marie de Tayrac, Marie-Dominique Galibert, Jean Mosser, Julien Edeline
Wichtige Hinweise
Héloïse Bourien and Alexandra Lespagnol have contributed equally.
Jean Mosser and Julien Edeline have contributed equally to this work.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



With the development of precision oncology, Molecular Tumor Boards (MTB) are developing in many institutions. However, the implementation of MTB in routine clinical practice has still not been thoroughly studied.

Material and methods

Since the first drugs approved for targeted therapies, patient tumor samples were centralized to genomic testing platforms. In our institution, all tumor samples have been analyzed since 2014 by Next Generation Sequencing (NGS). In 2015, we established a regional MTB to discuss patient cases with 1 or more alterations identified by NGS, in genes different from those related to drug approval. We conducted a retrospective comparative analysis to study whether our MTB increased the prescriptions of Molecular Targeted Therapies (MTT) and the inclusions of patients in clinical trials with MTT, in comparison with patients with available NGS data but no MTB discussion.


In 2014, 86 patients had UGA, but the results were not available to clinicians and not discussed in MTB. During the years 2015 and 2016, 113 patients with an UGA (unreferenced genomic alteration) were discussed in MTB. No patients with an UGA were included in 2014 in a clinical trial, versus 2 (2%) in 2015–2016. 13 patients with an UGA (12%) were treated in 2015–2016 with a MTT whereas in 2014, no patient (p = 0.001).


In this retrospective analysis, we showed that the association of large-scale genomic testing and MTB was feasible, and could increase the prescription of MTT. However, in routine clinical practice, the majority of patients with UGA still do not have access to MTT.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

e.Med Interdisziplinär

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf

Jetzt e.Med zum Sonderpreis bestellen!

Sichern Sie sich jetzt Ihr e.Med-Abo und sparen Sie 50 %!

Weitere Produktempfehlungen anzeigen
Über diesen Artikel
  1. Das kostenlose Testabonnement läuft nach 14 Tagen automatisch und formlos aus. Dieses Abonnement kann nur einmal getestet werden.